iSpecimen Inc.

NasdaqCM ISPC

iSpecimen Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: -73.97%

iSpecimen Inc. Return on Assets (ROA) is -73.97% for the Trailing 12 Months (TTM) ending September 30, 2024, a -53.23% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

iSpecimen Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -48.28%, a -51.32% change year over year.
iSpecimen Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -31.90%, a 53.80% change year over year.
iSpecimen Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -69.06%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: ISPC

iSpecimen Inc.

CEO	Ms. Leslie Hoyt
IPO Date	June 17, 2021
Location	United States
Headquarters	450 Bedford Street
Employees	53
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Key trends

Past 5 years